Abstract
We previously established (K. Sonoda et al., Int. J. Oncol., 6: 1099- 1104, 1995) a novel monoclonal antibody, 22-1-1, generated from adenocarcinoma of the uterine cervix, and 22-1-1 antigen (Ag) was expressed in cancer cells derived mainly from the uterus and ovary. In this report, a relationship between 22-1-1 Ag expression and clinicopathological variables and the prognostic significance of 22-1-1 Ag were immunohistochemically investigated in adenocarcinoma of the cervix. Of 56 cases, the 22-1-1 Ag was negative in 7, 1+ in 14, 2+ in 26 and 3+ in 9 instances. The 22-1-1 Ag existed both in the cytoplasm and on the membrane of cancer cells. There was no correlation between 22-1-1 Ag expression and age, stage, grade, myometrial invasion, lymph-vascular space invasion, lymph node metastasis, and parametrial invasion. The estimated 5-year overall survival (OS) of patients with low 22-1-1 Ag expression (-/+) and high 22-1-1 Ag expression (++/+++) were 90.5 and 71.4%, respectively. Patients with high 22-1-1 Ag expression had significantly worse OS than those with low 22-1-1 Ag expression (log- rank test, P = 0.0193). In addition, lymph-node metastasis, age, and clinical stage were significantly related to OS in univariate analysis. Multivariate analysis for OS revealed a prognostic significance in 22-1-1 Ag expression, stage, age, and grade. These data suggest that 22-1-1 Ag expression may be related to prognosis in adenocarcinoma of the cervix.
| Original language | English |
|---|---|
| Pages (from-to) | 1449-1453 |
| Number of pages | 5 |
| Journal | Clinical Cancer Research |
| Volume | 5 |
| Issue number | 6 |
| Publication status | Published - Jun 1 1999 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research
Cite this
The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix. / Kaku, Tsunehisa; Sonoda, Kenzo; Kamura, Toshiharu; Hirakawa, Toshio; Sakai, Kunihiro; Amada, Satoshi; Ogawa, Shinji; Kobayashi, Hiroaki; Nakashima, Manabu; Watanabe, Takeshi; Nakano, Hitoo.
In: Clinical Cancer Research, Vol. 5, No. 6, 01.06.1999, p. 1449-1453.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The prognostic significance of tumor-associated antigen 22-1-1 expression in adenocarcinoma of the uterine cervix
AU - Kaku, Tsunehisa
AU - Sonoda, Kenzo
AU - Kamura, Toshiharu
AU - Hirakawa, Toshio
AU - Sakai, Kunihiro
AU - Amada, Satoshi
AU - Ogawa, Shinji
AU - Kobayashi, Hiroaki
AU - Nakashima, Manabu
AU - Watanabe, Takeshi
AU - Nakano, Hitoo
PY - 1999/6/1
Y1 - 1999/6/1
N2 - We previously established (K. Sonoda et al., Int. J. Oncol., 6: 1099- 1104, 1995) a novel monoclonal antibody, 22-1-1, generated from adenocarcinoma of the uterine cervix, and 22-1-1 antigen (Ag) was expressed in cancer cells derived mainly from the uterus and ovary. In this report, a relationship between 22-1-1 Ag expression and clinicopathological variables and the prognostic significance of 22-1-1 Ag were immunohistochemically investigated in adenocarcinoma of the cervix. Of 56 cases, the 22-1-1 Ag was negative in 7, 1+ in 14, 2+ in 26 and 3+ in 9 instances. The 22-1-1 Ag existed both in the cytoplasm and on the membrane of cancer cells. There was no correlation between 22-1-1 Ag expression and age, stage, grade, myometrial invasion, lymph-vascular space invasion, lymph node metastasis, and parametrial invasion. The estimated 5-year overall survival (OS) of patients with low 22-1-1 Ag expression (-/+) and high 22-1-1 Ag expression (++/+++) were 90.5 and 71.4%, respectively. Patients with high 22-1-1 Ag expression had significantly worse OS than those with low 22-1-1 Ag expression (log- rank test, P = 0.0193). In addition, lymph-node metastasis, age, and clinical stage were significantly related to OS in univariate analysis. Multivariate analysis for OS revealed a prognostic significance in 22-1-1 Ag expression, stage, age, and grade. These data suggest that 22-1-1 Ag expression may be related to prognosis in adenocarcinoma of the cervix.
AB - We previously established (K. Sonoda et al., Int. J. Oncol., 6: 1099- 1104, 1995) a novel monoclonal antibody, 22-1-1, generated from adenocarcinoma of the uterine cervix, and 22-1-1 antigen (Ag) was expressed in cancer cells derived mainly from the uterus and ovary. In this report, a relationship between 22-1-1 Ag expression and clinicopathological variables and the prognostic significance of 22-1-1 Ag were immunohistochemically investigated in adenocarcinoma of the cervix. Of 56 cases, the 22-1-1 Ag was negative in 7, 1+ in 14, 2+ in 26 and 3+ in 9 instances. The 22-1-1 Ag existed both in the cytoplasm and on the membrane of cancer cells. There was no correlation between 22-1-1 Ag expression and age, stage, grade, myometrial invasion, lymph-vascular space invasion, lymph node metastasis, and parametrial invasion. The estimated 5-year overall survival (OS) of patients with low 22-1-1 Ag expression (-/+) and high 22-1-1 Ag expression (++/+++) were 90.5 and 71.4%, respectively. Patients with high 22-1-1 Ag expression had significantly worse OS than those with low 22-1-1 Ag expression (log- rank test, P = 0.0193). In addition, lymph-node metastasis, age, and clinical stage were significantly related to OS in univariate analysis. Multivariate analysis for OS revealed a prognostic significance in 22-1-1 Ag expression, stage, age, and grade. These data suggest that 22-1-1 Ag expression may be related to prognosis in adenocarcinoma of the cervix.
UR - http://www.scopus.com/inward/record.url?scp=0032979473&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032979473&partnerID=8YFLogxK
M3 - Article
C2 - 10389931
AN - SCOPUS:0032979473
VL - 5
SP - 1449
EP - 1453
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 6
ER -